相关实验视频

Updated: Sep 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

在前列腺癌中CDYL2b的抗瘤活性

Ruicai Gu¹, Julia Janknecht², Sangphil Oh³

¹Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

|August 14, 2025

概括

基因组脱甲基酶JMJD2A和JMJD2B抑制前列腺癌中的CDYL2基因. CDYL2b通过上调HES7和TBX6而起瘤抑制作用,而JMJD2B则对抗这种作用.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学

背景情况:

前列腺癌仍然是男性死亡的重要原因,其分子驱动因素尚未完全理解.
基因组脱甲基酶JMJD2A和JMJD2B与前列腺瘤发生有关.
表观遗传读者基因CDYL2在前列腺癌中的作用在很大程度上尚未被探索.

研究的目的:

研究CDYL2及其异型在前列腺癌中的作用.
阐明JMJD2A/JMJD2B和CDYL2.2之间的监管关系.
为了确定前列腺癌治疗的潜在治疗点.

主要方法:

在前列腺瘤中对CDYL2表达的生物信息分析.
描述CDYL2异型及其与色素的相互作用.
在体外和体内实验中,涉及前列腺癌细胞系和异种移植中的CDYL2b过度表达和下调.
RNA测序以识别CDYL2b调节的基因.
同免疫沉试验用于研究蛋白质相互作用.

主要成果:

低CDYL2表达与前列腺癌患者的转移,复发和生存率降低的增加有关.
只有CDYL2b异型在前列腺癌细胞中显著表达,并与染色质相关联.
过度表达CDYL2b抑制前列腺癌细胞生长和瘤扩张,而下调则促进生长.
CDYL2b对转录因子HES7,KLF17和TBX6进行上调,这些转录因子具有抗癌性质.
JMJD2B,但不是JMJD2A,与CDYL2b形成复合体,并对抗其提高调节HES7转录的能力.

结论:

CDYL2b作为前列腺癌中的瘤抑制剂,可能通过诱导HES7,KLF17和TBX6.
JMJD2A和JMJD2B通过抑制CDYL2b转录或活性来促进前列腺瘤发生.
发育转录因子TBX6和HES7也可能在前列腺癌中具有瘤抑制功能.

关键词:

在CDYL2中.表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.这种酶是JMJD酶.前列腺癌是什么意思前列腺癌是什么意思转录转录转录转录

更多相关视频

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...